Opendata, web and dolomites

MYCure SIGNED

Innovative cancer therapy through Myc inhibition: taking OMO-103 to market

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MYCure project word cloud

Explore the words cloud of the MYCure project. It provides you a very rough idea of what is the project "MYCure" about.

financing    capitals    14    scientific    builds    cancer    proteins    annually    accounting    redundant    commercialization    evolve    leadership    foundation    small    surface    2029    clinical    completing    omo    2018    tumours    efficient    too    bn    closed    contrast    cells    record    deaths    plan    first    treatments    acumen    despite    ground    venture    myc    resistance    rounds    sme    excellence    biotech    mycure    lung    survival    share    investments    kill    models    pharmaceutical    innovative    cell    companies    sound    millions    toxicity    treat    70    103    toxic    women    trials    therapies    combines    inhibitor    company    total    20    instrument    class    poised    attack    projected    receptors    considerable    market    global    full    ineffective    treatment    compensated    revolutionizing    nuclei    men    peptomyc    safer    equity    gain    penetrate    patented    world    addressable    breaking    2023    business    15    pressing    inhibition    thanks    licensing    clear    inhibiting   

Project "MYCure" data sheet

The following table provides information about the project.

Coordinator
PEPTOMYC SL 

Organization address
address: CENTER CELLEX, CALLE NATZARET 115-117
city: BARCELONA
postcode: 8035
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙170˙790 €
 EC max contribution 2˙219˙553 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PEPTOMYC SL ES (BARCELONA) coordinator 2˙219˙553.00

Map

 Project objective

Cancer is a global challenge with 9 millions (M) deaths annually and new cases projected to rise by 70% in the 20 years, and there is a clear and pressing need for more effective therapies. In the EU, lung cancer is the most common cancer in men and the third most common in women, with 2 M new cases in 2018 accounting for ~20% of all cancer deaths. Despite considerable recent advances in lung cancer treatment, current treatments are still too often ineffective or highly toxic. Peptomyc is a unique biotech SME that is revolutionizing cancer treatment with its ground-breaking innovative cancer therapies inhibiting Myc. Our patented product OMO-103 is able to penetrate the nuclei, attack Myc and kill cancer cells. In contrast, most current therapies attack redundant cell surface receptors or proteins that can be compensated by tumours, which then evolve resistance. Our company combines scientific excellence with sound business acumen: our scientific leadership in Myc inhibition builds on 20 years of world-class scientific record, and in just 3 years after the foundation, we closed 2 rounds of equity investments with Venture Capitals. Peptomyc aims at licensing its technology to pharmaceutical companies. Financing through this SME Instrument project will enable us to take to the market our first product, OMO-103 by completing clinical trials and reach a licensing agreement with a pharmaceutical company for full scale production and commercialization. Our results so far show that OMO-103 is: Safer (no toxicity), More efficient (no resistance observed), and More effective (increased survival in lung cancer models). With MYCure, we will take to market our first-in-class Myc inhibitor OMO-103 to treat non-small cell lung cancer, for which the global market is expected to reach 14 bn € by 2023, a total addressable market of which OMO-103 is poised to gain considerable share of up to 15% by 2029 thanks to a sound business plan developed under the SME Instrument.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYCURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYCURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

SMART UV (2019)

Intelligent Ultraviolet (UV) Radiation Filters

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More